This document is a publication of a European patent application (EP3322729A1) from the European Patent Office (EPO) concerning antibody molecules that bind CD45. The publication lists the applicant as UCB Biopharma SRL and provides inventor names and International Patent Classification (IPC) codes related to immunology and therapeutics. It also lists designated states within Europe where patent protection is sought.

As this is a patent publication, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it may be of interest to pharmaceutical and biotechnology companies involved in the development of antibody-based therapies, particularly those targeting CD45 for autoimmune diseases or cancer. Companies should monitor the patent prosecution process for potential future grant and associated intellectual property rights.